Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#SUBJECT> ?p ?o ?g. }
- SUBJECT label "Hyperbilirubinemia" assertion.
- SUBJECT label "the risk of reactivation" assertion.
- SUBJECT label "a total of 97 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "the remaining 3 patients" assertion.
- SUBJECT label "by antiviral prophylaxis" assertion.
- SUBJECT label "Four patients 4 1 " assertion.
- SUBJECT label "The median disease follow up time" assertion.
- SUBJECT label "Of Seven patientsHBsAg 4" assertion.
- SUBJECT label "10 1007 s10620 020 06725 1 " assertion.
- SUBJECT label "rheumatoid" assertion.
- SUBJECT label "supplementary material" assertion.
- SUBJECT label "Seven patients" assertion.
- SUBJECT label "TCZ" assertion.
- SUBJECT label "aperfused boundary regionPBR of the sublingual arterial microvessels increased PBR" assertion.
- SUBJECT label "dglobal" assertion.
- SUBJECT label "dglobal" assertion.
- SUBJECT label " n40 " assertion.
- SUBJECT label "endothelial function" assertion.
- SUBJECT label "to tocilizumabn40 or conventional synthetic disease modifying antirheumatic drugscsDMARDs and glucocorticoidsGC n40 " assertion.
- SUBJECT label "The percent improvement of glycocalyx thicknessPBR " assertion.
- SUBJECT label "Eighty rheumatoid arthritisRA patients" assertion.
- SUBJECT label "rheumatoid arthritisRA patients" assertion.
- SUBJECT label "rheumatoid arthritisRA patients" assertion.
- SUBJECT label "with csDMARDs GC" assertion.
- SUBJECT label "with baseline" assertion.
- SUBJECT label "This mechanism" assertion.
- SUBJECT label "Forty healthy subjects with similar age and sex" assertion.
- SUBJECT label "no difference in time to discharge" assertion.
- SUBJECT label "22 patients" assertion.
- SUBJECT label "considered" assertion.
- SUBJECT label "with tocilizumab combination group favipiravir and tocilizumab" assertion.
- SUBJECT label "the cumulative lung lesion remission rate" assertion.
- SUBJECT label "Between" assertion.
- SUBJECT label "This" assertion.
- SUBJECT label "In addition" assertion.
- SUBJECT label "The primary outcome" assertion.
- SUBJECT label "tocilizumab and favipiravir" assertion.
- SUBJECT label " lung CT examination" assertion.
- SUBJECT label "COVID 19" assertion.
- SUBJECT label "previous" assertion.
- SUBJECT label "The use of tocilizumab anakinra and prednisolone for COVID 19" assertion.
- SUBJECT label "previous medications immunosuppresive agents" assertion.
- SUBJECT label "adult patients who recovered from COVID 19 and were admitted to COVID 19 follow up unit" assertion.
- SUBJECT label "SARS CoV 2 IgG antibodies" assertion.
- SUBJECT label "SARS CoV 2 PCR positivity extent of lung involvement on CT time to antibody testing" assertion.
- SUBJECT label "The rate of antibody response and sample CO values among antibody positive patients" assertion.
- SUBJECT label "The main driver of antibody response among patients with COVID 19" assertion.
- SUBJECT label "anakinra or prednisolone use" assertion.
- SUBJECT label "a factor" assertion.
- SUBJECT label "A total of 518 patients" assertion.
- SUBJECT label "variables" assertion.
- SUBJECT label "by ELISA" assertion.
- SUBJECT label "we" assertion.
- SUBJECT label "we" assertion.
- SUBJECT label "we" assertion.
- SUBJECT label "we" assertion.
- SUBJECT label "we" assertion.
- SUBJECT label "Tocilizumab a humanized monoclonal antibody " assertion.
- SUBJECT label "Tocilizumab a humanized monoclonal antibody " assertion.
- SUBJECT label "The severity and mortality of COVID 19" assertion.
- SUBJECT label "Tocilizumab a humanized monoclonal antibody" assertion.
- SUBJECT label "the patients" assertion.
- SUBJECT label "IL 6" assertion.
- SUBJECT label "CRS cytokine release" assertion.
- SUBJECT label "a humanized monoclonal antibody" assertion.
- SUBJECT label "the interleukin 6 receptor" assertion.
- SUBJECT label "This article" assertion.
- SUBJECT label "to be not associated with better clinical outcomes and should be reserved for clinical trial scenario" assertion.
- SUBJECT label " tocilizumab s widespread use " assertion.
- SUBJECT label " tocilizumab s widespread use " assertion.
- SUBJECT label "Early treatment with Tocilizumab an anti soluble IL 6 receptor monoclonal antibody" assertion.
- SUBJECT label "Low dose administration of Tocilizumab an anti soluble IL 6 receptor monoclonal antibody " assertion.
- SUBJECT label "in COVID 19" assertion.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.
- SUBJECT label "A systematic review of Scopus , Web of Science , Pubmed Central , clinical trial databases and recent international rheumatology conferences for interventional and observational studies reporting the effectiveness of DMARDs in Takayasu arteritis ( TAK )" provenance.